Navigation Links
InterMune to Release Third Quarter 2008 Financial Results on November 6
Date:10/28/2008

BRISBANE, Calif., Oct. 28 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it will release third quarter 2008 financial results on Thursday, November 6, 2008 at 4:00 p.m. Eastern time. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

To access the live teleconference, dial 888-799-0528 (U.S.) or 706-634-0154 (international), conference ID# 71184785. To access the webcast, please log on to the company's website at http://www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 71184785.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
2. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
3. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
4. InterMune to Present at Canaccord Adams Conference
5. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
6. InterMune to Present at BMO Healthcare Conference
7. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
8. InterMune to Present at Jefferies Healthcare Conference
9. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
10. InterMune to Present at Citigroup Healthcare Conference
11. InterMune to Present at Bank of America Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Kinder Scientific (KinderScientific.com), a leading ... position the Company for the future. Kinder Scientific announces restructured ownership and ... been appointed Chairman of the Board, Curtis D. Kinghorn has been appointed CEO/President ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... a variety of fracture-specific plating options designed to address fractures of the distal ... fixation solutions. , The Acumed Ankle Plating System 3 is composed of seven ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... WEDI, the ... information exchange, today announced that Charles W. Stellar has been named by the WEDI ... CEO since January 2016. As an executive leader with more than 35 years of ...
(Date:5/24/2016)... 24, 2016   MedyMatch Technology Ltd ., the data ... real-time decision support tools in the emergency room, announced today ... Israeli Advanced Technology Industries (IATI) BioMed Conference. ... 15th National Life Sciences and Technology Week, and is ... Hotel in Tel Aviv, Israel . ...
Breaking Biology Technology:
(Date:3/15/2016)... , March 15, 2016 Yissum Research ... the technology-transfer company of the Hebrew University, announced today ... remote sensing technology of various human biological indicators. Neteera ... $2.0 million from private investors. ... on the detection of electromagnetic emissions from sweat ducts, ...
(Date:3/10/2016)... March 10, 2016 --> ... research report "Identity and Access Management Market by Component ... and Governance), by Organization Size, by Deployment, by Vertical, ... by MarketsandMarkets, The market is estimated to grow from ... by 2020, at a Compound Annual Growth Rate (CAGR) ...
(Date:3/8/2016)... 8, 2016   Valencell , the leading ... it has secured $11M in Series D financing. ... new venture fund being launched by UAE-based financial ... existing investors TDF Ventures and WSJ Joshua Fund. ... its triple-digit growth and accelerate its pioneering innovation ...
Breaking Biology News(10 mins):